In response to RFA-CA-12-007, Community Clinical Oncology Program (CCOP), National Cancer Institute, the Carle Cancer Center located in Urbana, Illinois is applying for continued funding as an East Central Illinois CCOP. The Carle Cancer Center CCOP, consisting of a main base and two components, has been continually funded since the inception of the CCOP in 1983. Carle, now an integrated healthcare organization, brings together a research-driven network of healthcare services. At the core of this network reside the Carle Foundation Hospital, Carle Physician Group and Health Alliance Medical Plans. With a 325-bed Level I trauma hospital, over 300 physician group, and a self-owned health insurance product, the Carle CCOP possesses the resources necessary to further its research mission. Joining the Carle CCOP as component institutions are Rush-Copley Medical Center in Aurora, Illinois and Franciscan St. Anthony Health in Michigan City, Indiana. Altogether, the catchment area consists of over 4 million people of which 1.3 million are minorities. The CCOP's primary research base is located in Urbana, Illinois where all registration, randomization, quality assurance, and data management are conducted. The CCOP's primary research base affiliation is with Alliance. Additionally, the Carle Cancer Center CCOP is long-standing members of the Eastern Cooperative Oncology Group (ECOG), the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), the Gynecological Oncology Group (GOG), and the Cancer Trials Support Unit (CTSU). Additionally, this past spring, the Carle Cancer Center CCOP joined the SunCoast CCOP Research Base. The Carle CCOP has recently experienced a doubling of accrual and fully anticipates accrual rates of 468 treatment subjects and 703 cancer control subjects over the next five years. With a dedicated research team of 12 investigators, over 50 staff members, and interactive administrative support, the CCOP is well-positioned to succeed. Based on a research-driven culture, seasoned and engaged investigators, and impeccable regulatory standards, the Carle CCOP is positioned to provide the highest level of care to the communities it serves.

Public Health Relevance

The Carle Cancer Center CCOP embraces the opportunity to participate in clinical trials that are designed to prevent cancer, control cancer related symptoms, and prolong disease-free survival in patients with diagnosed disease. The CCOP is committed to extending clinical trial opportunities to its predominantly rural population and increasing the research involvement of minority and underserved patient populations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA035195-30S1
Application #
8854221
Study Section
Special Emphasis Panel (ZCA1-SRLB-B (J1))
Program Officer
Good, Marge
Project Start
1990-06-01
Project End
2014-07-31
Budget Start
2013-06-27
Budget End
2014-07-31
Support Year
30
Fiscal Year
2014
Total Cost
$121,369
Indirect Cost
$24,601
Name
Carle Foundation
Department
Type
DUNS #
075606517
City
Urbana
State
IL
Country
United States
Zip Code
61801
Leal, Alexis D; Qin, Rui; Atherton, Pamela J et al. (2014) North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer 120:1890-7
Loprinzi, Charles L; Qin, Rui; Dakhil, Shaker R et al. (2014) Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol 32:997-1005
Province, M A; Goetz, M P; Brauch, H et al. (2014) CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther 95:216-27
Van Loon, Katherine; Espinoza, Anne M; Fogelman, David R et al. (2014) Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas 43:343-9
Dronca, Roxana S; Allred, Jacob B; Perez, Domingo G et al. (2014) Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675. Am J Clin Oncol 37:369-76
Atherton, Pamela J; Halyard, Michele Y; Sloan, Jeff A et al. (2013) Assessment of patient-reported measures of bowel function before and after pelvic radiotherapy: an ancillary study of the North Central Cancer Treatment Group study N00CA. Support Care Cancer 21:1193-9
Barton, Debra L; Burger, Kelli; Novotny, Paul J et al. (2013) The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9. Support Care Cancer 21:1185-92
Barton, Debra L; Liu, Heshan; Dakhil, Shaker R et al. (2013) Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. J Natl Cancer Inst 105:1230-8
Wolf, Sherry L; Barton, Debra L; Qin, Rui et al. (2012) The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA. Support Care Cancer 20:625-32
Kottschade, Lisa A; Suman, Vera J; Amatruda 3rd, Thomas et al. (2011) A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1). Cancer 117:1704-10

Showing the most recent 10 out of 147 publications